Strata Skin Sciences working with CMS to obtain temporary codes for XTRAC

STRATA Skin Sciences (SSKN) announced it is working with the Centers for Medicare & Medicaid Services, CMS, to obtain temporary codes that would accelerate access to recently expanded reimbursement for its XTRAC excimer laser treatment. “Expanding access to XTRAC is about more than increasing device utilization and revenue per device-it’s about helping millions of patients who are living with chronic, inflammatory skin conditions, with limited long term safe, efficacious and accessible treatment modalities,” said Dr. Dolev Rafaeli, STRATA Skin Sciences President and CEO. “By working with CMS to secure temporary reimbursement ahead of 2027, we aim to bring this safe, effective, non-drug therapy to a broader patient population-more than 30 million people-sooner, while creating more substantial economic incentives for providers to deliver this care, for which they are paid vs. prescribing expensive, less effective medication for which they are not.